Viveve Medical (VIVE) Given Buy Rating at Mizuho

Viveve Medical (NASDAQ:VIVE)‘s stock had its “buy” rating reissued by analysts at Mizuho in a research note issued on Friday. They presently have a $10.00 price target on the stock. Mizuho’s price objective indicates a potential upside of 101.21% from the company’s previous close.

Other equities research analysts have also issued research reports about the stock. Cowen set a $11.00 price target on shares of Viveve Medical and gave the company a “buy” rating in a report on Monday, October 23rd. Northland Securities assumed coverage on shares of Viveve Medical in a research report on Friday. They issued an “outperform” rating and a $8.00 price objective on the stock. Finally, ValuEngine downgraded shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $10.00.

Viveve Medical (NASDAQ:VIVE) traded down $0.22 during trading hours on Friday, hitting $4.97. 250,000 shares of the stock were exchanged, compared to its average volume of 138,267. The company has a current ratio of 3.89, a quick ratio of 3.63 and a debt-to-equity ratio of 2.72. Viveve Medical has a 1 year low of $3.75 and a 1 year high of $11.16. The stock has a market capitalization of $96.55, a PE ratio of -2.31 and a beta of -0.67.

Viveve Medical (NASDAQ:VIVE) last posted its earnings results on Wednesday, November 8th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.08). Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The company had revenue of $4.07 million for the quarter, compared to analysts’ expectations of $4.10 million. During the same period in the previous year, the business posted ($0.46) earnings per share. The business’s revenue was up 120.1% on a year-over-year basis. sell-side analysts forecast that Viveve Medical will post -2.04 EPS for the current year.

Large investors have recently bought and sold shares of the business. Rhumbline Advisers acquired a new position in Viveve Medical during the second quarter worth $110,000. JPMorgan Chase & Co. acquired a new position in Viveve Medical during the second quarter worth $151,000. Virtu KCG Holdings LLC acquired a new position in Viveve Medical during the second quarter worth $169,000. Schwab Charles Investment Management Inc. acquired a new position in Viveve Medical during the second quarter worth $189,000. Finally, California State Teachers Retirement System acquired a new position in Viveve Medical during the second quarter worth $190,000. Institutional investors own 66.90% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3127192/viveve-medical-vive-given-buy-rating-at-mizuho.html.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.